WCM
ALXN

WealthBridge Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History

WealthBridge Capital Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-310
Closed -$41K – 962
2019
Q1 		$41K Sell
310
-91
-23% -$11.3K 0.03% 320
2018
Q4 		$39K Buy
+401
New +$47.4K 0.03% 292

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

WealthBridge Capital Management's ALXN Position: Q2 2019 in Review

WealthBridge Capital Management sold out of Alexion Pharmaceuticals (ALXN) in Q2 2019, closing a stake of 310 shares — an estimated $41K sold.

WealthBridge Capital Management first reported a position in ALXN in Q4 2018 and held it in 2 quarters. The position peaked at $41K in Q1 2019. 636 funds tracked by Wall St. Rank hold ALXN as of Q2 2019.

  • WealthBridge Capital Management reported no remaining Alexion Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • WealthBridge Capital Management sold 310 Alexion Pharmaceuticals shares in Q2 2019, an estimated $41K.
  • WealthBridge Capital Management first reported a position in Alexion Pharmaceuticals in Q4 2018 and held it in 2 quarters.
  • WealthBridge Capital Management's Alexion Pharmaceuticals position peaked at $41K in Q1 2019.
  • 636 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2019.

Based on WealthBridge Capital Management's 13F filing for Q2 2019, filed 13 Aug 2019.